logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – 4 out of 7 complete responses in first study of neoadjuvant ipilimumab plus nivolumab in mismatch repair deficient colon cancer

Early results from the NICHE study confirm efficacy of immunotherapy against mismatch repair deficient (dMMR) early colorectal cancer